Global Point of Care Diagnostics Market

1
Point of Care Diagnostics Market 2026 by Global
Outlook with Sales Assistance "The global point
of care diagnostics market was valued at US
17,886.3 Mn 2018 and is expected to reach US
30,175.3 Mn 2026, growing at a CAGR of 6.8
during the forecast period." High prevalence of
chronic and infectious diseases in developing
countries, and rapid technological advancements
to drive the growth of the global Point of Care
Diagnostics market According to the Sekisui
Diagnostics, there are nearly 9,000 urgent care
centers in the US that cater to the demand for
point of care diagnostics from more than 160
million patients every year. Additionally, the
survey of primary care patients in the US found
that the 77 of patients prefer lab services
on-site. Furthermore, the survey concluded that
the labs and X- rays done on-site is one of the
latest trend in the global point of care
diagnostics market during the forecast period.
Get Free Sample Report with Tables and Figures_
https//www.alltheresearch.com/sample-request/248
The high prevalence of chronic and infectious
diseases in developing countries, rapid
technological advancements, and shortage of
availability of skilled laboratory technicians
are the major driving factors for the global
point of care diagnostics market during the
forecast period. Furthermore, the rising
inclination of physicians and healthcare
providers to use point-of-care devices owing to
various advantages of these devices such as
ease-of- use and rapid diagnosis which
facilitates better diagnosis and disease
management, has led to increasing adoption of
these devices in healthcare settings. The
prevalence of target diseases in the developed
and developing countries and rising demand for
home healthcare services are expected to create
opportunities in the global market during the
forecast period. According to the US National
Library of Medicine National Institutes of Health
and Centers for Disease Control, the chronic
diseases in the US accounted for nearly 75 of
aggregate healthcare spending, or an estimated
USD 5,300 per person per year. Point of care
diagnostics, also referred to as near-patient or
bedside testing, includes the use of medical
devices for the quick diagnosis of various
diseases including diabetes, cardiovascular
diseases, and cancer, amongst others. Such test
includes glucose and cholesterol level tests,
pregnancy test, cardiac markers, blood test,
enzyme analysis, and various other tests for
infectious diseases. The main advantages to of
point-of-care testing such as ease-of-use and
rapid diagnosis which facilitates better
diagnosis and management, has led to increasing
adoption of these devices in healthcare
settings. For Other Requirement_
https//www.alltheresearch.com/customization/248
Company Profiles and Competitive Intelligence
2

• The major players operating in the global point
  of care diagnostics market are Abbott
  Laboratories (US), F. Hoffmann-La Roche Ltd
  (Switzerland), Danaher Corporation (US), Becton
  Dickinson Company (US), Quidel Corporation
  (US), Sekisui Diagnostics LLC (US), Siemens
  Healthcare GmbH (Germany), and Trinity Biotech
  (US) and bioMérieux SA (France) among others.
  Other prominent players in the market are PTS
  Diagnostics, OraSure Technologies, Nova
  Biomedical, Chembio Diagnostics Systems Inc, and
  EKF Diagnostics amongst others.
• However, the stringent regulatory policies in the
  developed countries are expected to hamper the
  market growth of the point of care diagnostics
  during the forecast period.
• Key Findings
• Based on products, the infectious disease testing
  segment is expected to grow at a CAGR of 9.1
  during the forecast period. Rapid diagnosis of
  infectious diseases aid timely treatment and
  also help in improving the prescribing patterns
  and facilitate the containment of infectious
  disease outbreaks. This will lead to increased
  adoption of infectious disease PoC tests by
  physicians
• Based on prescription mode, the OTC-based testing
  segment is expected to grow at the highest CAGR
  during the forecast period
• North America to account for more than 37 share
  in the market
• Homecare DTC end-user segment to grow at the
  highest CAGR during the forecast period
• Recent News
• In July 2019, Polyscope Polymers B.V. (Geleen,
  Netherlands) developed an engineering
  thermoplastic alloy i.e. styrene maleic anhydride
  (SMA) and polymethyl methacrylate (PMMA) for
  point of care diagnostics devices. The
  commercialization of these material is expected
  by the end of 2019.
• In December 2017, Sekisui Diagnostics and Mesa
  Biotech entered into a strategic alliance for
  Molecular POC Testing System. Under the terms of
  the agreement, Sekisui Diagnostics holds
  exclusive distribution rights for Mesa Biotech's
  POC molecular system for Flu A/Flu B. This
  partnership will help further strengthen
  Sekisui's Flu testing portfolio.
• In 2017, Abbott completed the acquisition of
  Alere Inc. for a price of around 5.3 billion.
  Alere has a very vast portfolio of point-of-care
  testing products, with a broad menu of handheld
  and benchtop infectious disease testing products,
• cardiometabolic testing products, and toxicology
  testing products. This acquisition has helped
  Abbott enhance their product portfolio.
• Continue.....
• More Clear Details Make Enquiry_
  https//www.alltheresearch.com/speak-to-analyst/24
  8

3
AllTheResearch was formed with the aim of making
market research a significant tool for managing
breakthroughs in the industry. As a leading
market research provider, the firm empowers its
global clients with business-critical research
solutions. The outcome of our study of numerous
companies that rely on market research and
consulting data for their decision-making made
us realize, that its not just sheer data-points,
but the right analysis that creates a
difference. For all your Research needs, reach
out to us at 39180 Liberty Street Suite 110,
Fremont, CA 94538, USA Email contactus_at_alltheres
earch.com US 1-888-691-6870